A NOVEL THERAPEUTIC APPROACH USING BIOTECHNOLOGY ON PHARMACEUTICAL PRODUCTS
Objective: The present review focus on biotechnology medicines, therapeutic agents obtained from genes, recombinant DNA, developments in protein drug delivery, regulatory aspects of biotechnology-based pharmaceuticals, formulation approaches to protein stabilization, methods used to evaluate protein pharmaceuticals, Production of Biopharmaceuticals from Recombinant DNA Technology. Conclusion: For treatment of disease, therapeutic agents are derived from biotechnology have been approved for human use. Recombinant protein products are developing as a part of pharmaceutical development. The advancement in technology mapping or the genome, explosive growth of the targets identified.
J. Sterling, The next decade of biotechnology. Where are we going? J. Parenter. Sci. Technol., 44, 63 (1990).
Pharmaceutical Manufacturer’s Association, Products in the pipeline, Biotechnology, 9, 947 (1991).
W. Sadee, Protein drugs: A revolution in therapy? Phann. Res., 3, 3 (1986).
W. J. Black, Drug products of recombinant DNA technology, Am. J. Hosp. Pharm., 46, 1834 (1989).
L. P. Gage. Biopharmaceuticals: Drugs of the future, Am. J. Phann. Ede., 50, 368 (1986).
F. G. Banting and C. H. Best, Pancreatic extracts, J. Lab. Clin. Med., 7, 464 (1922).
J. D. Baxter, Recombinant DNA and medical progress, Hosp. Pract., 15, 57 (1980).
P. Brown, C. C. Gajdusek, C. J. Gibbs, and D. N. Asher, Potential epidemic of Creutzfeldt-Jakob disease from human growth hormone therapy, N. Engl. J. Med., 313(12), 728 (1985).
J. D. Watson, J. Tooze, and D. T. Kurtz, Recombinant DNA: A Short Course, W.H. Freeman and Co., New York, 1983.
R. L. Rodriguez and R. C. Tait, Recombinant DNA Techniques: An Introduction, Addison-Wesley Publishing, Reading, MA, 1983.
G. Kohler and C. Milstein, Continuous cultures of fused cells secreting antibody of predefined specificity, Nature, 256, 495 (1975).
J. Richards, J. Auger, D. Peace, D. Gale, J. Michel, Koons, T. Haverty, R. Zivin, L. Jolliffe, and J. Bluestone, Phase I evaluation of humanized OKT3: toxicity and immune modulatory effects of hOKT3- gamma4, Cancer Res., 59(9), 2096 (1999).
S. L. Morrison and V. T. Oi, Genetically engineered antibody molecules, Adv. Immunol., 44, 65 (1989).
Duncan, N. M. Avdalovic, M. Levitt, R. P. Junghans, and T. A. Waidman, A humanized antibody that binds to the interleukin 2 receptor, Proc. Natl. Acad. Sci. USA, 86, 10029 (1989).
L. Reichmann, L. M. Clarke, H. Waldman, and Winter, Reshaping human antibodies for therapy, Nature, 332, 323 (1988).
J. Newman, J. Albert, D. Anderson, K. Carner, C. Heard, F. Norton, R. Raab, M. Reff, S. Shuey, and N. Hanna, Primatization of recombinant antibodies for immunotherapy of human diseases: A macaque/human chimeric antibody against human CD4, Biotechnology, 10, 1455 (1992).
L. K. Gilliland, L. A. Walsh, M. R. Frewin, M. P. Wise, M. Tone, G. Hale, D. Kioussis, and H. Waldmann, Elimination of the immunogenicity of therapeutic antibodies, J. Immunology, 162(6), 3663 (1999).
S. D. Gorman and M. R. Clark, Humanization of monoclonal antibodies for therapy Semin. Immunol., 2, 457 (1990).
S. Porter, Human immune response to recombinant proteins, J. Pharmaceut. Sci., 90(1), 1 (2001).
R. A. Dwek, Glycobiology: Toward understanding the function of sugars, Chem. Rev., 96, 683 (1996).
S. Patterson, Biologics and biotechnology products, PDA J. Pharm. Sci. Technol., 52(6), 316 (1998).
L. Stryer, Biochemistry, W. H. Freeman, San Francisco, 1981.
F. Franks, Characterization of Proteins, Humana Press, Clifton, NJ, 1988.
R. D. Schmid, Stabilized soluble enzymes, Adv. Bio¬ chem. Eng., 12, 42 (1979).
D. B. Volkin and A. M. Klibanov, Minimizing protein inactivation, in Protein Function: A Practical Approach (T. E. Creighton, ed.), IRL Press, Oxford, 1989, pp. 1-24.
Copyright (c) 2019 Mintage Journal of Pharmaceutical and Medical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.